

# President Annual Activity Report for 2020

Nicolaus Kröger, EBMT President

## Science

#### COVID-19

In terms of activity, 2020 was severely affected by the COVID-19 pandemic but despite the challenges, EBMT was able to demonstrate a strong commitment to its patients and members by providing:

- guidelines for transplant units, recipients, and donors of hematopoietic cells.
   These guidelines have been updated each time new information was obtained about COVID-19 epidemiology and clinical outcome.
- COVID-19 vaccines information produced by the IDWP

   also available on the EBMT website.
- 9 COVID-focus webinars for physicians and nurses, organised with other sister societies

https://www.ebmt.org/covid-19-and-bmt

#### The Registry

750

Source: EBMT Registry, December 2020

#### New Registrations for Cellular Therapy in 2020

EBMT has actively encouraged centres to report on all cases involved in the treatment of patients using a CAR-T product whether commercial or investigational.

All centres should continue to complete the current Cell Therapy Form outlined in ProMISe on a timely basis to create an accurate patient representation.

The graph below illustrates the steady growth of new reported cases into the EBMT Registry during 2020 and the reflected number of centres.

Number of CAR-T cell treated patients registered in the EBMT Registry 1500 Patients treated with commercial CAR-T cells 1250 Number of patients Patients treated with 1000 investigational CAR-T cells


> July Aug Sept Oct Nov Dec Jan Feb Mar Apr MayJune July Aug Sept Oct Nov Dec

The map below represents a geographical approach in blue of all our reporting countries who are continually submitting data to the EBMT Registry.



#### **The Registry** - Registry Upgrade Project

The Registry upgrade project has faced several challenges during the course of 2020, and these caused a complete halt of the data migration mid-year. Due to the high priority of this project, a thorough analysis on behalf of the EBMT was carried out. Looking at several technical as well as functional issues, this has resulted in a comprehensive Test plan created by the vendor. Together with the vendor, an approach was defined in order to address all the identified issues, find solutions and build towards a strong foundation to continue the project as a whole.



Outcomes of these tests are expected in the Q1 of 2021, whereafter new Validation and Test plans will be developed by the Registry in order to complete the data migration.

#### The Registry - Resource

In 2020 the Registry has transitioned form the previous Head, Debra Gordon, to the new Registry Director, Bas Middelkoop, who joined the EBMT Registry in December 2020.

Due to the loss of two members of staff in 2020 the Registry has been looking to replace the two vacancies and succeeded. Two experienced Data Analysts have joined the Registry IT department in Q1 of 2021. Also the Registry is looking to expand the team further in 2021, giving the Registry team more hands and expertise to face the challenges for the coming year.

#### **Collaboration with Kite**

In June 2020, the EBMT announced a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a CAR T cell therapy.

Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data for 20 years from patients treated with Yescarta® in the EBMT registry for cellular therapy.

## Education

### 46th Annual Meeting [Virtual]


On March 4<sup>th</sup> 2020, EBMT decided to postpone the Meeting until the end of August.

On April 2<sup>nd</sup>, reported global COVID-19 infections reached one million.

On May 6<sup>th</sup>, EBMT announced that it's Annual Meeting would be going fully virtual for the first time, ever.



Despite the ongoing pandemic, the objective of EBMT with regards to education remained unchanged – to share leading cutting-edge science and to provide the highest quality of education in the field of stem cell transplantation and cellular therapy.



#### Other educational events

LOCATION	DATES	Nº PARTICIPANTS	WORKING PARTIES	TITLE
	24-25 January 2020		CMWP	Chronic Malignancies Working Party Meeting
Sitges (Barcelona), Spain	30 Jan - 1 February 2020	1000 / Livestreaming: 189	EBMT - EHA	2nd European CAR T Cell Meeting
Virtual	8-10 July 2020	377	PDWP, SAAWP, IEWP, NG	Midterm Focus Meeting on Non-Malignant Diseases
Virtual	29 Aug - 1 Sep 2020	6,783	ЕВМТ	46th Annual Meeting of the European Society for Blood and Marrow Transplantation
Virtual	24-25 September 2020	217	ADWP	Autoimmune Diseases Working Party Meeting
Virtual	25 September 2020	74	IEWP	Inborn Errors Working Party Business Meeting
Virtual	8-9 October 2020	134	NG	12th Nurses International Study Day & 4th Nurses Research Study Day Meetings
Virtual	10 October 2020	37	CMWP	Chronic Malignancies Working Party Meeting
Virtual	28-30 October 2020	124	IDWP	23rd Infectious Diseases Working Party Meeting
Virtual	4-6 November 2020	373* platform opened until Feb 2	ЕВМТ	5th International Transplant Course

#### **E-learning**

Another important development in EBMT Education in 2020 was the launch of the **e-learning platform**.

- ➤ The e-learning taskforce laid out the strategy for the advancement of online education.
- ➤ The e-learning unit provided with COVID-19 webinars in April/May, followed by an increased demand for all types of online learning.
- ➤ Now all EBMT Members have access to a multitude of resources which are available for free, such as webinars, e-courses, forums, exams and more.

# **Advocacy & Quality of Care**

#### **GoCART Coalition**

- In November 2020, the EBMT and EHA announced a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.
- The two societies join forces and bring their collective resources and expertise to the newly founded <u>GoCART coalition</u>.

# JACIE – Standards and Accreditation in 2020



JACIE's 2020 activity was severely affected by the pandemic from mid-March. **40 applications** were received, **18 inspections** were completed before on-site inspections were cancelled and **47 accreditations** were awarded.

JACIE is developing a **remote inspection process** to be launched in the first quarter of 2021.

#### **JACIE - Other**

#### Benchmarking

The FACT-JACIE Standards require centres to review their clinical outcomes against wider datasets, referred to as benchmarking. EBMT as a registry holder is in a unique position to offer an international benchmarking scheme to centres that report data.

In October 2020, the first phase of this service was launched whereby reports of data-completeness were provided to 416 qualifying centres for the period 2013-2016. The second phase in February 2021 will see the provision of clinical outcome benchmarking reports to those centres that have met the data completeness threshold.

Benchmarking will thereafter become an annual exercise. The next edition will be in June 2021 based on 2015-2019 data.

#### 8th Edition of FACT-JACIE Standards

The process to prepare the 8th edition of the FACT-JACIE Standards continued throughout 2020. The first draft was opened for public consultation in April 2020 for 3 months. 770 comments from 78 participants in 12 countries were received and that feedback was reviewed by the Standards sub-committees during the last quarter of 2020 before the final draft will be presented to the FACT and EBMT Boards for approval in early 2021.

The definitive text will be published in May 2021.

#### The Nurses Group activities 2020

#### **Working Party Nurses:**

This role is now firmly established as a valuable resource in each of the medical working parties. The goal to develop collaborative nursing/medical projects for patient benefit continues to develop at pace. The roles have begun to adapt to the needs of the WP with many nurses taking more responsibility for education. There have been 2 papers published by the PDWP with nursing input this year. There is currently 1 nurse vacancy in the inborn errors WP.

- 4 Publications
- 2 Oral presentations
- **6 Educational events**

#### **Nursing Education:**

- COVID-19 webinars for nurses (Palliative Care guidance for patients with severe COVID-19; Psychological impact of COVID-19 pandemic on nurses: experiences and tips)
- Preparation of the E-textbook for nurses: it will be available on the elearning platform.

#### Other key achievements

- Reinforcement of the collaborative relationship with our sister societies -CIBMTR, ASTCT and APBMT - with respect to data collection harmonisation and scientific exchange.
- Opening of an EBMT Office in Shanghai (China) with the objective to promote convenient and in-depth exchange between the Chinese haematology community and the EBMT, strengthen multi-centre clinical innovation and cooperation, share scientific experience, standards and protocols, and ultimately provide the best treatment and care for patients.
- Presentation of the EBMT new logo and name as well as the refocused mission, vision and core values—which better represent worldwide involvement and modernity.

#### Other key achievements

- Creation of the so-called 'Equality, Diversity and Inclusion' (EDI) working
  group to address our society's gender imbalance at senior levels as well as to
  promote broader equality, diversity and inclusion issues, and ultimately aiming to
  improve the inclusion of people across gender, ethnicity, geography, and social
  categories.
- Release of the Patient Engagement Survey, on behalf the EBMT Patient Engagement Taskforce, to understand the current point of view of all EBMT stakeholders (i.e. health care providers, industry staff, government officials, patients, donors and caregivers) regarding the engagement of patients in HCT and cell therapy data-collection and research.
- Launch of the **EBMT Trainee Committee** with the overall aim of addressing the specific needs of trainees working in BMT and cellular therapy, as well as providing advice and support for trainees at all levels.

#### 2020 elections and revised organigram

John Snowden (Sheffield, UK), Secretary
Raffaella Greco (Milan, Italy), ADWP Chair
Rafael de la Cámara (Madrid, Spain), IDWP Chair
Bertram Glass (Berlin, Germany), LWP Chair









From left to right: J. Snowden; R. Greco; R. de la Cámara; B. Glass

- Medical Officer: Isabel Sánchez-Ortega
- EBMT restructuration in 5 departments:
  - 1. Support
  - 2. Sales
  - 3. Registry
  - 4. Clinical Research
  - 5. Education & Events



# Thanks!

